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Abstract Racial differences among hepatocellular carci-
noma survival have been reported, but the etiology behind
these disparities remains unclear. Using multi-variable
logistic regression analysis, our restrospective cohort study
investigated the demographic disparities in survival among
localized hepatocellular carcinoma in the United States.
From 1998 to 2001, 2,776 cases of localized hepatocellular
carcinoma were identiﬁed. Signiﬁcant racial/ethnic dis-
parities in overall survival and utilization of therapies were
identiﬁed. Compared with non-Hispanic white males, black
females were 56% less likely to survive 3 years (OR 0.44;
95% CI 0.21–0.93). Treatment-speciﬁc models also dem-
onstrated disparities, e.g., compared with non-Hispanic
whites, Asians receiving transplantation were 77% more
likely to survive 3 years (OR, 1.77; 95% CI 1.28–2.44).
There are signiﬁcant racial/ethnic disparities in 3-year
survival among patients with localized hepatocellular car-
cinoma. These differences are partially explained by
demographic differences in utilization of therapy and in
stage-speciﬁc survival for each therapy.
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Introduction
Hepatocellular carcinoma ranks among the deadliest can-
cers worldwide [1–7]. Despite advances in screening and
early detection, hepatocellular carcinoma retains a poor
prognosis, with overall 1- and 5-year survival rates of 23
and 5%, respectively [8, 9]. However, small, localized
tumors may be more amenable to curative therapy and
substantially improved survival [8–13]. The emergence of
more effective screening and surveillance protocols, com-
bined with improvements in curative therapy for early
stage cancers, provides the opportunity to identify popu-
lations that may beneﬁt most from invasive therapies and
investigate modiﬁable disparities in the application of these
treatments.
Recent studies have reported racial/ethnic variations in
the rising incidence of hepatocellular carcinoma [14–18].
Some have also suggested that racial/ethnic variations exist
in survival outcomes among patients diagnosed with this
cancer [10–13, 19–26]. However, these studies were lim-
ited by the generalizability of their patient population or
did not include detailed data on more advanced therapies
commonly used in the United States. One of these studies
included only Medicare-recipients who, because of age and
comorbid conditions, may be less likely to receive
aggressive interventions (e.g., resection or liver transplan-
tation). No study to date has focused speciﬁcally on
localized cancers, the type most likely to respond to ther-
apeutic interventions [10–12, 25, 26]. A detailed analysis
of survival after a localized tumor diagnosis would provide
the greatest information on whether survival differences
exist by race, ethnicity, and gender and whether these
differences are due to differences in the use of speciﬁc
treatments for the same stage of disease, different respon-
ses to treatment, or other factors. In the last decade, the
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and End Results (SEER) cancer registry has incorporated
more detailed information on therapeutic interventions;
these data now permit a population-based assessment for
treatment disparities, treatment responses, and survival for
different demographic groups.
We performed a study utilizing high-quality data from
the SEER cancer registry to evaluate whether race and
ethnicity were associated with survival after the diagnosis
of localized stage hepatocellular carcinoma, adjusted for
sex, age, year of diagnosis, and treatment type. We then
evaluated whether survival differences were explained by
geographic or demographic disparities in treatment
administered or demographic differences in the response to
treatment.
Methods
Data Sources
We analyzed data from the SEER registry, a population-
based cancer registry covering approximately 26% of the
US population, for the years 1998–2004 (the most recent
year of data). The SEER population is comparable to the
general US population with regards to measures of poverty
and education [27]. Prior to 1998, the SEER program
compiled only basic information for cancer-directed sur-
gical therapies. Starting in 1998, SEER registries added
detailed therapeutic interventions such as ablation, trans-
plantation, etc. The 1998–2004 data set includes data from
registries in 17 geographic regions: Atlanta, Connecticut,
Detroit, Hawaii, Iowa, New Mexico, California (San
Francisco–Oakland, Los Angeles, San Jose-Monterey, and
Greater California, which includes Central California,
Sacramento, Tri-County, Desert Sierra, Northern Califor-
nia, San Diego/Imperial County, Orange County), Seattle-
Puget Sound, Utah, Rural Georgia, the Alaska Native
Tumor Registry, Kentucky, Louisiana, and New Jersey
[27, 28].
Case Deﬁnitions
Cases of hepatocellular carcinoma were identiﬁed using
anatomic site (liver: C22.0) and histology codes (hepato-
cellular carcinoma: 8170–8175) from the International
Classiﬁcation of Disease for Oncology, 3rd ed. [29].
Hepatocellular carcinoma, NOS (8170), accounted for
98.9% of our cases. Localized cancers were classiﬁed using
SEER staging criteria [30]; a ‘‘localized’’ SEER stage
included cancers conﬁned to one lobe of the liver (with or
without vascular invasion), and without evidence of nodal
or extrahepatic involvement.
Race/Ethnicity Deﬁnitions
Our analyses utilized the following SEER race and eth-
nicity categories: non-Hispanic whites, blacks, Asian/
Paciﬁc Islanders (Asian/PI), and Hispanic whites (His-
panics). The small number of cancer cases among other
groups (American Indian/Alaskan, black Hispanics, Asian/
PI Hispanics) precluded the calculation of precise estimates
for these populations.
Treatment Deﬁnitions
The SEER database includes information regarding the
type of therapy received by each patient. Among patients
receiving multiple treatments (e.g., radiation prior to
resection), only the ﬁrst treatment is recorded. We grouped
therapeutic interventions into ﬁve categories: no invasive
therapy, local tumor destruction (including photodynamic
therapy, electrocautery, cryosurgery, laser, percutaneous
ethanol injection, and local tumor destruction not otherwise
speciﬁed [NOS]), radio frequency ablation, resection
(wedge, segmental, or lobectomy), and liver transplantation
[30].
Outcome Deﬁnitions
The main outcome was the proportion of persons surviving
3 years after a localized hepatocellular carcinoma diagno-
sis. This outcome (rather than shorter intervals) was chosen
given the overall 3-year survival for localized hepatocel-
lular carcinoma in our data set was\30% and the 3-year
interval decreased the impact of lead time bias from
detection for any demographic group. Detailed treatment
data and follow-up was available for the years 1998–2004;
thus, a case diagnosed in 2001 had 3 years of follow-up
available. Longer intervals (e.g., 5 years) provided rela-
tively few cases for analysis.
Statistical Analysis
Analyses were performed using the SEER*Stat 6.5.3
(National Cancer Institute, Maryland) and Stata statistical
packages (release ten, Stata Corporation, Texas). Odds
ratios (OR) and 95% conﬁdence intervals (CI) were cal-
culated using logistic regression models, with an outcome
variable of 3-year survival; we did not use hazard ratios to
decrease lead or length time biases incorporated into time-
to-event analyses. Multivariable logistic regression models
were adjusted for sex, age, year of diagnosis, race/ethnic-
ity, and therapeutic intervention. Geography (via SEER
registry location) was also evaluated as a potential con-
founder. Our study focused on the ﬁve geographic regions
with [450 total hepatocellular carcinoma cases (San
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123Francisco-Oakland, Detroit, Los Angeles, Greater Califor-
nia, and New Jersey) to ensure enough statistical power to
assess differences among treatment distribution between
ethnic subgroups.
Results
Overview
The mean proportion of persons surviving three years after
a localized hepatocellular carcinoma diagnosis during the
period 1973–1997 was 18.1% (95% CI 15.9–20.3), with the
lowest proportion among blacks (10.0%; 95% CI 6.5–13.5)
and the highest among Asian/PI (23.0%; 95% CI 19.9–
26.1). For the 1998–2001 time interval, the 3-year survival
proportions for cases diagnosed were higher for the group
as a whole (28.1%; 95% CI 26.3–29.9) and for each race/
ethnicity group compared with cancers diagnosed between
1973 and 1997 (Table 1).
Distribution of Therapy by Type and Geographic
Region
We investigated whether differences in survival by race/
ethnicity were explained by variations in therapy received.
The administration of any invasive intervention was high-
est among Asian/PI (38.9%; 95% CI 35.0–42.1) and lowest
among Hispanics (25.5%; 95% CI 21.7–29.3) (Table 2).
For speciﬁc treatments, Asian/PI were the most likely to
receive hepatic resection (24.5%; 95% CI 21.6–27.9) and
Hispanics were the least likely (9.4%; 95% CI 7.1–12.3).
Non-Hispanic whites were the most likely to receive liver
transplantation (9.4%; 95% CI 8.0–11.0) and blacks were
the least likely (4.8%; 95% CI 2.7–7.9). The proportions
receiving local tumor destruction therapy and radio fre-
quency ablation were similar among all racial/ethnic
groups.
We evaluated whether the differences in treatment
received were due to geographic differences. If a given
region, for example, was more likely to provide hepatic
resection as a treatment and that region had a higher
proportion of Asian/PI, geography may confound the
association between hepatic resection and Asians/PI.
Geography, however, did not explain the treatment differ-
ences seen. The use of speciﬁc therapies differed markedly
by geographic region between the ﬁve SEER regions that
reported at least 450 cases, but the general patterns of
treatment differences by race/ethnicity were similar within
each region (Table 3). Similar to the pooled data from all
registries, within each region Asian/PI were generally more
likely to receive resection, non-Hispanic whites and His-
panics were more likely to receive transplantation, and
Table 1 Three-year survival in patients diagnosed with localized hepatocellular carcinoma, stratiﬁed by race/ethnicity
Cases diagnosed from 1973 to 1997 Cases diagnosed from 1998 to 2001
Male and female 3 year survival (%) 95% CI Total cases 3 year survival (%) 95% CI Total cases
Non-Hispanic white 18.1 15.9–20.3% 1,556 28.3 25.8–30.8% 1,328
Black 10.0 6.5–13.5% 324 18.8 13.9–23.7% 275
Asian/PI 23.0 19.9–26.1% 770 32.6 28.9–36.3% 697
Hispanic white 15.4 11.5–19.3% 364 26.1 22.0–30.2% 476
SEER dataset time periods, 1973–1997 versus 1998–2001 (with subsequent 3-year survival data through 2004)
Table 2 Distribution of invasive therapies administered, stratiﬁed by
race/ethnicity, among patients with localized hepatocellular carci-
noma (years 1998–2004)
Therapy Count Percent (%) 95% CI
Non-Hispanic white
No invasive therapy 1,033 67.8 65.4–70.2
Radio frequency ablation 28 1.8 1.2–2.6
Local tumor destruction 73 4.8 3.8–6.0
Resection 246 16.1 14.3–18.1
Transplant 143 9.4 8.0–11.0
Black
No invasive therapy 228 73.6 68.3–78.4
Radio frequency ablation 6 1.9 0.7–4.2
Local tumor destruction 15 4.8 2.7–7.9
Resection 46 14.8 11.1–19.3
Transplant 15 4.8 2.7–7.9
Asian/PI
No invasive therapy 457 61.1 57.9–65.0
Radio frequency ablation 12 1.6 0.8–2.8
Local tumor destruction 47 6.3 4.7–8.3
Resection 183 24.5 21.6–27.9
Transplant 44 5.9 4.3–7.9
Hispanic white
No invasive therapy 395 74.5 70.7–78.3
Radio frequency ablation 12 2.3 1.2–3.9
Local tumor destruction 29 5.5 3.7–7.8
Resection 50 9.4 7.1–12.3
Transplant 43 8.1 5.9–10.8
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123blacks were less likely to receive any treatment. For
example, in Detroit only 5.2% of blacks received trans-
plantation compared with 12.8% of non-Hispanic whites
(P\0.02). Even among Asian/PI, who generally were
more likely to receive some treatment, signiﬁcant differ-
ences in transplantation were identiﬁed (6.2% in Asians/PI
vs. 12.5% in non-Hispanic whites; Los Angeles, P\0.01)
(Table 3). Age and gender adjusted analyses for the com-
parisons presented above were all statistically signiﬁcant
(P\0.05).
Adjusted Survival Analyses
Race/ethnic differences in the proportion surviving 3 years
still persisted after adjustment for therapy type, age, and
year of diagnosis. For example, compared to non-Hispanic
white males (the largest group), black females were 56%
less likely to survive at least 3 years (OR 0.44; 95% CI
0.21–0.93) and Asian/PI males were 31% more likely to
survive at least 3 years (OR 1.31; 95% CI 1.00–1.72)
(Table 4).
Treatment Response
We evaluated whether the survival disparities were
explained by demographic differences in the response to
each treatment modality, given adjustment for treatment
type alone did not eliminate the survival differences for
localized disease. We compared survival for each treatment
regimen vs. no treatment, stratiﬁed by sex or race/ethnicity,
and adjusted for age and year of diagnosis.
The response to local tumor destruction was lower in
females than in males (females: 19.5% 3-year survival, OR
2.00, 95% CI 0.91–4.39; males: 46.3% survival, OR 7.57,
95% CI 5.06–11.33). In contrast, 3-year survival rates were
comparable between males and females for surgical
resection, transplantation, and radio frequency ablation.
For both males and females, patients receiving transplan-
tation were the most likely to survive 3 years (males:
80.2% survival, OR 26.94, 95% CI 18.07–40.18; females:
80.4% survival, OR 19.76, 95% CI 10.04–38.90) (Table 5).
The response to therapy for local stage disease varied by
race/ethnicity, even after adjustment for sex, age, and year
Table 3 Distribution of therapy for SEER registries with[450 cases of hepatocellular carcinoma, stratiﬁed by race/ethnicity (years 1998–2004)
SEER Registry No invasive therapy Local destruction RFA Resection Transplant
Percent Count Percent Count Percent Count Percent Count Percent Count
SF–Oakland
Non-Hispanic white 67.2 178 3 8 3.8 10 12.8 34 13.2 35
Black 73.2 41 0 0 1.8 1 14.3 8 10.7 6
Asian 58.5 172 1.4 4 6.1 18 23.5 69 10.5 31
Hispanic white 67.1 51 0 0 7.9 6 14.5 11 10.5 8
Detroit
Non-Hispanic white 62.4 181 5.9 17 3.1 9 15.9 46 12.8 37
Black 69.7 108 7.1 11 5.2 8 12.9 20 5.2 8
Asian 70.6 12 0 0 0 0 23.5 4 5.9 1
Hispanic white 66.7 6 0 0 11.1 1 11.1 1 11.1 1
Los Angeles
Non-Hispanic white 64.8 234 3.6 13 3.3 12 15.8 57 12.5 45
Black 79.1 83 1.9 2 0 0 10.4 12 6.7 7
Asian 63.1 243 5.7 22 5.5 21 19.1 74 6.2 24
Hispanic white 74.1 280 4.2 16 1.9 7 8.7 33 11.1 42
Greater CA
Non-Hispanic white 64.6 506 5.5 43 8.1 63 12.4 97 9.3 73
Black 68.6 59 2.3 2 7 6 18.6 16 3.5 3
Asian 60.9 201 6.1 20 9.7 32 17 56 5.5 18
Hispanic white 72.4 318 4.8 21 5.7 25 6.4 28 10.5 46
New Jersey
Non-Hispanic white 50.3 189 8.8 33 9.3 35 14.1 53 16.5 62
Black 49.5 51 19.4 20 4.9 5 17.5 18 8.7 9
Asian 40 26 7.7 5 7.7 5 33.9 22 9.2 6
Hispanic white 48.1 37 20.8 16 6.5 5 11.7 9 11.7 9
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123of diagnosis (Table 6). For any given treatment, compared
with non-Hispanic whites, Asian/PI had trends for the
greatest overall survival after treatment, whereas blacks
had the least beneﬁt, although some conﬁdence intervals
overlapped 1.00. For example, Asian/PI who received
transplants for limited stage disease were 77% more likely
to be alive 3-years postdiagnosis than similar non-Hispanic
whites matched for age, sex, and year of diagnosis (OR
1.77, 95% CI 1.28–2.44). In contrast, there was a strong
trend for blacks to be less likely to survive 3 years after
resection, compared with non-Hispanic whites (OR 0.65,
95% CI 0.42–1.01). These general trends were similar for
all treatment modalities including local tumor destruction
therapy, radio frequency ablation, resection, and
transplantation.
Discussion
Among patients with localized hepatocellular carcinoma,
our study identiﬁed substantial and signiﬁcant differences
Table 4 Multivariable logistic regression analysis of 3-year survival by sex and race/ethnicity
Predictor variable 3-year survival % Cases OR 95% CI OR 95% CI
Age and date adjusted Age, date, and treatment adjusted
Non-Hispanic white male 27.8 998 1.00 Reference 1.00 Reference
Non-Hispanic white female 29.7 330 1.48 1.12–1.94 1.19 0.86–1.65
Black male 21.7 193 0.65 0.45–0.95 0.81 0.52–1.24
Black female 12.0 82 0.40 0.20–0.80 0.44 0.21–0.93
Asian/PI male 33.2 497 1.39 1.10–1.76 1.31 1.00–1.72
Asian/PI female 31.2 200 1.47 1.06–2.05 1.41 0.95–2.08
Hispanic white male 24.8 338 0.81 0.61–1.08 1.04 0.74–1.47
Hispanic white female 29.3 138 1.19 0.79–1.79 1.37 0.85–2.20
Cases include localized hepatocellular carcinoma diagnosed from 1998 to 2001 (with 3-year follow-up through 2004). The 3-year survival is a
crude (unadjusted) value
Table 5 Multivariable logistic regression analysis of 3-year survival
by category of invasive therapy received
Predictor variable 3-year
survival
Adjusted
OR
95% CI
Male
No invasive therapy 11.9% 1.00 Reference
Radio frequency
ablation
44.1% 6.11 3.15–11.87
Local tumor destruction 46.3% 7.57 5.06–11.33
Resection 53.4% 8.98 6.86–11.76
Transplant 80.2% 26.94 18.07–
40.18
Female
No invasive therapy 13.0% 1.00 Reference
Radio frequency
ablation
44.0% 2.89 0.95–8.84
Local tumor destruction 19.5% 2.00 0.91–4.39
Resection 56.8% 8.31 5.52–12.50
Transplant 80.4% 19.76 10.04–
38.90
The 3-year survival proportion is a crude (unadjusted) value. This
odds ratio is adjusted for age, year of diagnosis, and race/ethnicity
among localized HCC diagnosed from 1998 to 2001 (with 3-year
follow-up through 2004)
Table 6 Multivariable logistic regression analyzing the association
between 3-year survival and category of invasive therapy received
stratiﬁed by race/ethnicity
Predictor variable Adjusted OR 95% CI
Radio frequency ablation
Non-Hispanic white 1.00 Reference
Black 0.71 0.41–1.24
Asian/PI 2.03 1.45–2.83
Hispanic white 1.14 0.77–1.69
Local tumor destruction
Non-Hispanic white 1.00 Reference
Black 0.66 0.39–1.13
Asian/PI 1.69 1.22–2.32
Hispanic white 1.22 0.85–1.76
Resection
Non-Hispanic white 1.00 Reference
Black 0.65 0.42–1.01
Asian/PI 1.50 1.16–1.95
Hispanic white 1.13 0.80–1.58
Transplant
Non-Hispanic white 1.00 Reference
Black 0.84 0.51–1.40
Asian/PI 1.77 1.28–2.44
Hispanic white 1.24 0.86–1.78
The 3-year survival proportion is a crude (unadjusted) value. The
odds ratio is adjusted for sex, age, and year of diagnosis among
localized HCC diagnosed from 1998 to 2001 (with 3-year follow-up
through 2004)
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123by race/ethnicity in overall 3-year survival, type of therapy
administered for limited stage disease, and survival after
speciﬁc therapies. Compared with non-Hispanic whites,
blacks were less likely to survive 3 years after diagnosis,
less likely to receive any treatment, and, when treated, less
likely to survive 3 years for most speciﬁc treatment types;
the lowest survival times were found in black females. In
contrast, Asian/PI had the highest 3-year survival out-
comes, were the most likely to receive any treatment
(particularly resection), and, when treated, had better 3-
year survival outcomes for each speciﬁc treatment type.
Although the likelihood of treatment varied somewhat by
geographic region, demographic disparities in receipt of
therapy existed in most geographic regions and geography
did not explain the overall patterns of survival or treatment
by race/ethnicity (Table 3). While our study focused on
regions where the number of localized hepatocellular car-
cinoma cases exceeded 450 for purposes of statistical
analysis, the same discrepancies persisted even among
more rural areas of the country that were not included in
Table 3. For example, in the Kentucky registry, 12.8% of
non-Hispanic whites received liver transplantation com-
pared with 6.3% of blacks. Similarly, among patients with
localized hepatocellular carcinoma in Louisiana, 19.2% of
non-Hispanic whites received transplantation compared
with 11.7% of blacks.
Current estimates of survival outcome among patients
diagnosed with hepatocellular carcinoma are concerning.
Between 1977 and 1996, 1-year survival improved from 14
to 23%, but overall and longer-term survival remained poor
[8]. Patients with localized cancers have the greatest
potential for beneﬁt from therapeutic interventions. One
study among 4,008 patients diagnosed with hepatocellular
carcinoma between 1988 and 1998 reported a 5-year sur-
vival of 33% among those with small, unifocal, non-
metastatic cancers who underwent surgical intervention
compared with a 7% 5-year survival among those who did
not receive surgery [11]. The same study noted that 45% of
patients with potentially resectable tumors did not receive
surgery. Additional studies investigating treatment out-
comes have also suggested possible underutilization of
potentially curative therapy among patients with localized
cancers [10–13].
The current study extends prior reports that evaluated
demographic variables and hepatocellular carcinoma [10–
26]. A prior study in Medicare patients suggested geo-
graphic differences in treatment for hepatocellular
carcinoma; however, it is unclear if the results in this
population (median age 74 years) can be generalized given
older patients may be less likely to receive aggressive
interventions such as liver transplantation [10]. Prior
studies that utilized the SEER database found racial/ethnic
differences in survival overall, but this was prior to the
availability of recent detailed data on therapeutic inter-
ventions (such as radio frequency ablation, tumor
destruction by electrocautery or fulguration, cryosurgery,
laser, and percutaneous ethanol injection) that were eval-
uated in the current study, and there were not detailed
analyses of limited stage disease, the stage most responsive
to treatment [10, 12, 13, 26]. Furthermore, a survival
analysis that includes all stages of cancers may be con-
founded by variations in treatment availability and utility
as more aggressive cancers may not be offered invasive
therapies. Thus, the current analysis included all ages,
expanded data on therapeutic interventions, and focused
speciﬁcally on localized cancers, which have the greatest
potential to demonstrate a survival beneﬁt and to identify
any disparities that may exist.
Our ﬁndings suggest that demographic differences in the
likelihood of receiving treatment and responses to treatment
may at least partially underlie the described differences in
survival outcome by race/ethnicity. Racial disparities in
receipt of surgical therapy have been suggested by others as
well [19, 20, 23, 24]. Demographic differences in the
delivery of health care are well documented [31, 32]; for
example, blacks and women are less likely to receive
aggressive cardiac interventions in the presence of coronary
artery disease [33–35]. Potential explanations include
unequal access to health care, inappropriate overuse in other
groups, physician attitudes towards disease risk in different
demographic groups, patient attitudes towards medical care,
and overt discrimination [36, 37]. In addition, major inter-
ventions such as transplantation require the fulﬁllment of
rigid criteria for social support, adherence to medical care,
etc.. Meeting these criteria may be more challenging for
immigrant groups or persons of lower socioeconomic stat-
ure—the groups which are proportionately more likely to
include minority populations.
Differences in outcome after speciﬁc treatments may
also be partially related to the underlying diseases associ-
ated with hepatocellular carcinoma, most commonly
hepatitis B, hepatitis C, and alcohol abuse. These risk
factors are not in the SEER database and could not be
evaluated in the current analysis. The biological behavior
of hepatocellular carcinoma may differ in the presence of
different risk factors. For example, while hepatitis C
causing hepatocellular carcinoma is almost always pre-
ceded by progressive liver damage resulting in cirrhosis,
hepatitis B can lead to hepatocellular carcinoma without
liver cirrhosis. These differences likely affect choice of
therapy and overall survival. Hepatitis B virus is the main
etiological agent for hepatocellular carcinoma in Asians,
while hepatitis C virus is more commonly found in blacks
and non-Hispanic whites [38–46]. While few studies have
reported variations in surgical interventions, one study
suggested that compared to non-Hispanic whites, Asians
2036 Dig Dis Sci (2009) 54:2031–2039
123with chronic hepatitis B virus had a signiﬁcantly higher
posttransplantation mortality [23]. A differential response
to similar interventions between demographic groups sug-
gests the possibility that ethnicity/race may inﬂuence
posttherapy survival independent of etiology; such differ-
ences are well documented for many disorders, including
hypertension and the response to antiviral therapies for
hepatitis C [47–50]. Potential explanations for the race/
ethnicity-speciﬁc variations in treatment response in our
study include differences in disease severity within limited
stage disease, host genetic variations to therapy or the
cancer, compliance with therapy, disparities in co-inter-
ventions that inﬂuence survival, or interactions with
environmental factors.
Strengths of this study include the utilization of high-
quality data from a population-based cancer registry that
represents a large proportion of the US population [27, 28].
Detailed data on race classiﬁcations and therapeutic inter-
ventions permitted analysis of sex and race/ethnicity-
speciﬁc responses to each treatment category and the
analyses adjusted for several potential major confounders
including age, date of diagnosis, and gender among local-
ized cancers.
There are several potential limitations of this study. In
Table 1, we presented improvements in 3-year survival
between patients with localized hepatocellular carcinoma
diagnosed between 1973 and 1997 and those diagnosed
between 1998 and 2001. While the increased survival rates
likely represent new advances in cancer targeted therapy
and improved techniques of potentially curative interven-
tions, lead time bias may also be another contributing
factor. In addition, SEER records the initial therapy
received after a cancer diagnosis, but not necessarily the
most aggressive therapy. Some patients may have received
multiple treatments over time; however, this limitation of
all registry studies does not alone explain the race/ethnicity
differences in treatment patterns or posttreatment survival.
Although all patients analyzed had localized disease, a
spectrum of disease exists within each recorded cancer
stage. While the SEER category of ‘‘localized tumors’’ is
deﬁned by lack of nodal or extrahepatic involvement, it is
limited in its ability to identify the extent of tumor
involvement (size and unifocal vs. multifocal) within the
lobe it affects as well as evidence of vascular invasion.
Tumor differences within the category of localized disease
may inﬂuence the utility of therapy for some patients,
although it is not clear that racial/ethnic disparities in the
spectrum of disease within each stage would fully account
for the differences observed in treatment, treatment
response, and overall survival. Even if this were the case, it
would suggest there are either biological differences in
disease aggressiveness within a speciﬁc stage between the
different race/ethnic groups or differences in the
application of techniques (e.g., screening) between the
groups to identify less aggressive cancers. Either of these
would be important observations for improving treatment
outcomes. Finally, additional factors such as disease eti-
ology (e.g., viral hepatitis), underlying liver disease,
severity of liver disease as evidenced by MELD scores,
other comorbidities, alcohol use, access to timely care
within each SEER region, etc., were not available for
analysis; variations in these factors may also inﬂuence
choices of therapeutic intervention employed or survival
and may differ by race/ethnicity.
In summary, for localized stage hepatocellular carci-
noma, this study described substantial and signiﬁcant
disparities by race/ethnicity in 3-year survival, therapy
administered, and stage-speciﬁc survival for individual
therapies. The differences were not explained by age, date
of diagnosis, or geography. Potential explanations include
differences in the delivery of health care between demo-
graphic groups with similar stages of disease, disease
differences within limited stage disease, disease biology, or
variations in treatment response.
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